Management of people with diabetes wanting to fast during Ramadan

BMJ (Online)

Volumn 340, Issue 7761, 2010, Pages 1407-1411

  Hui, E ^a   Bravis, V ^a   Hassanein, M ^b   Hanif, W ^c   Malik, R ^d   Chowdhury, T A ^e   Suliman, M ^f   Devendra, D ^a,g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

^f ROYAL PRESTON HOSPITAL   (United Kingdom)

^g EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SULFONYLUREA; VILDAGLIPTIN;

CLINICAL TRIAL; DIET RESTRICTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; RELIGION; REVIEW; RISK ASSESSMENT;

BLOOD GLUCOSE; DIABETES MELLITUS; DIET; EXERCISE; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; ISLAM; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

EID: 77954115541     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c3053     Document Type: Review

References (31)

1. Rashed AH. The fast of Ramadan. BMJ 1992;304:521-2.
2. Koran 2:183-5.
3. Salti I, Be'nard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11.
4. Beshyah SA. Fasting during the month of Ramadan for people with diabetes: medicine and Fiqh united at last. Ibnosina Journal of Medicine and Biomedical Sciences 2009;1:58-60.
5. Uysal A, Erdogan MF, Sahin G, Kamel N, Erdogan G. Clinical and metabolic effects of fasting in 41 type 2 patients during Ramadan. Diabetes Care 1998;21:2033-4. (Pubitemid 28478319)
6. Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetologia 2009;46:63-5.
7. Cesur M, Corapcioglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Research and Clinical Practice 2007;75:141-7.
8. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, et al. American Diabetes Association recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305-11.
9. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan education and awareness in diabetes programme for Muslims with type 2 diabetes who fast during Ramadan. Diabetes Medicine 2010;27:327-31.
10. Mojaddidi M, Hassanein M, Malik R. Ramadan and diabetes: evidence-based guidelines. Prescriber 2006;Sep:38-41.
11. Benaji B, Mounib N, Roky R, Aadil N, Houti IE, Moussamih S, et al. Diabetes and Ramadan: review of the literature. Diabetes Res Clin Pract 2006;73:117-25.
12. Muslim Spiritual Care Division in the NHS. Ramadan Health Factsheet 2009. A project of the Muslim Council in Partnership with the department of Health. Available from Muslim Spiritual Care Provision in the NHS, PO box 57330, London E1 2WJ; nhsspiritualcare@mcb.org.uk
13. National Institute for Health and Clinical Excellence. Type 2 diabetes-newer agents (partial update of CG66). (Clincal guideline 87.) 2009. http://guidance.nice.org.uk/CG87.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
15. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99.
16. Rosak C, Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Current Diabetes Review 2009;5:157-64.
17. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Medicine 2008;25:435-41. (Pubitemid 351490110)
18. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58(1):45-53. (Pubitemid 34823624)
19. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocrine Research 2004;30:169-77. (Pubitemid 39243119)
20. Belkhadir J, El-Ghomari H, Klocker N, Mikou A, Nasciri M, Sabri M. Muslims with noninsulin-dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-5. (Pubitemid 23220845)
21. Glimperide in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2.
22. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Medical Journal of Malaysia 2006;61:28-35. (Pubitemid 43667242)
23. Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446-50.
24. Vasan S, Thomas N, Bharani, Ameen M, Abraham S, Job V, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries 2006;26:70-6.
25. Norris SL, Lee N, Thakurta S, Chan BKS. Exenatide efficacy and safety: a systematic review. Diabetes Medicine 2009;26:837-46.
26. Bravis V, Hui E, Salih S, Hassanein M, Devendra D. A comparative analysis of exenatide and gliclazide during the month of Ramadan. Diabetic Medicine 2010;27(suppl 1):130.
27. Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Ramadan Study Group. Diabetes Res Clin Pract 2003;59:137-43.
28. Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract 2010;March 10 (epub ahead of print; www3.interscience.wiley.com/ journal/123318627/abstract).
29. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Charovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
30. Azar ST, Khairallah WG, Merheb MT, Zantout MS, Fliti F. Insulin therapy during Ramadan fast for patients with type 1 diabetes mellitus. Journal Medical Libanais 2008;56(1):46.
31. Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al Arouj M, Akram J, et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metabolism 2001;27:482-6. (Pubitemid 32852457)